Center for Medical Mycology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA.
Methods Mol Biol. 2022;2517:317-328. doi: 10.1007/978-1-0716-2417-3_25.
With the recent emergence of multidrug-resistant Candida auris, there is an urgent need for new antifungal compounds with novel pharmacodynamic and pharmacokinetic properties that can treat systemic fungal infections caused by this emerging yeast. Historically, testing the efficacy of treatment for disseminated candidiasis was accomplished using a diverse array of in vivo animal models, including mice which offer an advantage both in their similarities to humans and their lower cost of maintenance. However, in order to create effective in vivo models for testing new antifungal compounds designed to treat systemic infections, it is important that these models also mimic several of the relevant predisposing conditions that can lead to disseminated candidiasis. Here, we describe an immunocompromised mouse model of hematogenously disseminated C. auris infection, which may have utility to test the efficacy of candidate antifungal compounds.
随着多重耐药性念珠菌的出现，我们急需具有新型药效学和药代动力学特性的新型抗真菌化合物来治疗这种新兴酵母菌引起的系统性真菌感染。从历史上看，通过使用各种体内动物模型来测试治疗播散性念珠菌病的疗效，其中包括在相似性和成本效益方面都具有优势的小鼠。然而，为了创建用于测试旨在治疗系统性感染的新型抗真菌化合物的有效体内模型，这些模型还需要模拟导致播散性念珠菌病的几种相关诱发条件。在这里，我们描述了一种血源播散性 C. auris 感染的免疫功能低下小鼠模型，该模型可能对测试候选抗真菌化合物的疗效具有实用性。
